A0e56275e699418ebe79128c1b3ed894

Page 1

CURRICULUM VITAE Mohan Suntharalingam, MD, MBA The Marlene and Stewart Greenebaum Professor of Radiation Oncology University of Maryland School of Medicine

DATE:

March, 2014

OFFICE ADDRESS

University of Maryland School of Medicine Department of Radiation Oncology 22 S. Greene Street, GGK0101 Baltimore, MD 21201 E-mail: msuntha@umm.edu (410) 328-2331 (410) 328-6911 fax

CURRENT ADMINISTRATIVE ROLE President & CEO UMMS/St. Joseph Medical Center Vice President for System Program Development University of Maryland Medical System

EDUCATION 1982 - 1986

A.B. – Human Biology (Biology & Psychology) – Brown University Providence, Rhode Island

1986 - 1990

M.D. – Jefferson Medical College – Philadelphia, PA

2007 – 2009

MBA – The Wharton School of Business - University of Pennsylvania Philadelphia, PA.

POST GRADUATE TRAINING 1990 – 1991

Internship in Internal Medicine, Bryn Mawr Hospital Bryn Mawr, Pennsylvania

1991 – 1993

Resident in the Department of Radiation Oncology University of Maryland Medical Systems – Baltimore, MD

1


POST GRADUATE TRAINING – Continued 1993 – 1994

Chief Resident in the Department of Radiation Oncology University of Maryland Medical Systems – Baltimore, MD

1994 – 1995

Clinical Oncology Fellow of the American Cancer Society University of Maryland Medical Systems – Baltimore, MD

SUB-SPECIALTY ROTATION DURING RESIDENCY TRAINING 1/93

Breast Service, Department of Radiation Oncology Thomas Jefferson University Hospital Philadelphia, PA

3/94

Head and Neck Service, Department of Radiation Oncology University of Florida, Gainesville, FL

5/94

Pediatric Service, Department of Radiation Oncology St. Jude Children’s Research Hospital Memphis, TN

3/95

Conformal Therapy Research Program Christie Hospital, Manchester, England Royal Marsden Hospital, London, England

CERTIFICATION 6/91

Diplomat of the National Board of Medical Examiner

6/95

Certification in Radiation Oncology by the American Board of Radiology

5/05

Re-Certification in Radiation Oncology by the American Board of Radiology

LICENSE

Maryland License #: D0047618

FACULTY APPOINTMENTS 7/95 – 6/01

Assistant Professor Department of Radiation Oncology University of Maryland School of Medicine

7/01 – 6/04

Associate Professor Department of Radiation Oncology University of Maryland School of Medicine

7/04 – 7/06

Associate Professor with Tenure Department of Radiation Oncology University of Maryland School of Medicine

7/06 – Present

Professor with Tenure Department of Radiation Oncology

2


University of Maryland School of Medicine ADMINISTRATIVE APPOINTMENTS 8/97 – 12/12

Vice Chairman Department of Radiation Oncology University of Maryland School of Medicine

1/03 – 1/06

Associate Director for Multidisciplinary Program Development and Outreach University of Maryland Marlene and Stewart Greenebaum Cancer Center

1/06 – 12/12

Associate Director of Clinical Affairs, University of Maryland Marlene and Stewart Greenebaum Cancer Center

7/06 – Present

Director Program of Excellence in Technology Based Translational Research Department of Radiation Oncology University of Maryland School of Medicine (Direct oversight of a planned $5 million endowed research program)

3/08 – Present

Associate Director Radiation Oncology Residency Program University of Maryland Medical System

3/08 – 07/09

Director - Program of Excellence in Technology Based Translational Research Department of Radiation Oncology University of Maryland School of Medicine

CLINICAL APPOINTMENTS 7/95 – Present

Member, Program in Oncology University of Maryland Marlene and Stewart Greenebaum Cancer Center

10/95 – 8/97

Acting Clinical Director Department of Radiation Oncology University of Maryland School of Medicine

8/97 – 12/12

Clinical Director Department of Radiation Oncology University of Maryland School of Medicine

6/02 – 9/08

Medical Director Department of Radiation Oncology Baltimore Washington Medical Center

1/03 – 9/09

Director of Clinical/Translational Research Department of Radiation Oncology University of Maryland School of Medicine

PROFESSIONAL MEMBERSHIPS • • •

1986 – Present 1991 – 1995 1991 – 1995

The Omega Psi Phi Fraternity American Medical Association Member Association of Residents in Radiation Oncology

3


• •

1991 – Present 1991 – Present

American College of Radiation Oncology American Society for Therapeutic Radiology and Oncology

PROFESSIONAL MEMBERSHIPS - Continued • • • •

1995 – Present 1997 – Present 2000 2000

Simon Kramer Society (Vice Chairman) Radiation Therapy Oncology Group American College of Radiology American Radium Society

AWARDS & HONORS •

1988 – 1990

Amory Hare Medical Honor Society

1995

Clinical Oncology fellowship in Conformal Therapy, Sponsored by The American College of Radiation Oncology

1999

Nominated for the Lane W. Adams Award sponsored by The American Cancer Society

2005

Best Doctors in America, Best Doctors, Inc.

2007

Best Doctors in America, Best Doctors, Inc.

2007

Top Doctors, Baltimore Magazine

2008

Endowed Professorship, University of Maryland Marlene and Stewart Greenebaum Cancer Center

2009-2010

Best Doctors in America, Best Doctors, Inc.

INSTITUTIONAL COMMITTEES 1996

Member – CALGB Clinical Research Committee University of Maryland Marlene and Stewart Greenebaum Cancer Center

1996

Member – Oncology Network Development and Implementation Team University of Maryland Medical Center

1997

Member – Clinical Productivity Design Team Office of the Dean, University of Maryland at Baltimore

1996 - 1997

Member – Search Committee, Deputy Director for Clinical Affairs University of Maryland Marlene and Stewart Greenebaum Cancer Center

1996 - 1999

Director, Esophageal Cancer Section, Thoracic Malignancy Task Force University of Maryland Marlene and Stewart Greenebaum Cancer Center

1996 - Present

Member – University of Maryland School of Medicine Council

1996 - Present

Member – Clinical Research Committee University of Maryland Marlene and Stewart Greenebaum Cancer Center

4


1996 - Present

Member – Cancer Committee, University of Maryland Marlene and Stewart Greenebaum Cancer Center.

INSTITUTIONAL COMMITTEES – Continued 1996 - 2000

Member, Baltimore VA Medical Center Cancer Committee

1996 - 2000

Member – Total Body Irradiation Task Force Department of Radiation Oncology University of Maryland School of Medicine

1998 - Present

Member – Cancer Review Committee University of Maryland Marlene and Stewart Greenebaum Cancer Center Member – Cancer Center Research Council University of Maryland Marlene and Stewart Greenebaum Cancer Center

2002 - Present 2002

Member – Cancer Council University of Maryland Marlene and Stewart Greenebaum Cancer Center

2003

Member – Dean’s Search Committee for Position of Chairman of the Department of Otolaryngology, University of Maryland School of Medicine

2003 - Present

Member – Bicentennial Planning Committee, University of Maryland School of Medicine

2004 - Present

Member – Ambulatory Care Project Opening Group University of Maryland Medical Center

2007

LCME Institutional Self Study Educational Resources Subcommittee

2007

Member - Commitment to Excellence Committee – Physician Partnership Group University of Maryland Medical Center

EDITORIAL POSITIONS 1995 – Present

Ad hoc reviewer, International Journal of Radiation Oncology Biology Physics

1997 – Present

Ad hoc reviewer, Cancer

1999 – Present

Ad hoc reviewer, Journal of Clinical Oncology

2005 - Present

Editorial Board, Cancer Investigation

2006 – Present

Editorial Board, Journal of Surgical Oncology

EDUCATIONAL / TEACHING ACTIVITIES 1991 – Present

Medical Student Education-Monthly Lecturer in Clinical Radiation Oncology for Rotating Medical Students 2-4 hours/month

1993 – 1994

Coordinator of Education Program For Residents in Radiation Oncology

1993 – 1995

Coordinator, Grand Rounds/Visiting Professor Lectureship schedule of The University of Maryland School of Medicine, Department of Radiation Oncology

5


1995 – Present

Weekly Multidisciplinary Thoracic Malignancy Conference – 1 hr/wk

EDUCATIONAL / TEACHING ACTIVITIES – Continued 1995 – Present

Radiation Oncology Resident Research Preceptor 2 hrs/week

1995 – Present

Radiation Oncology Resident Education Annual lectures in Clinical Radiation Oncology Morning quality assurance/teaching conference Monday Journal Club Mock Oral Board Examiner 8 hrs/week

1995 – Present

Departmental Advisor/Research Mentor for Medical Students Entering the field of Radiation Oncology

1996 – Present

Otolaryngology Resident Education Annual lectures in Clinical Radiation Oncology 3 hrs/year

1997 – Present

Gastroenterology Fellow Education Annual lecture in Clinical Radiation Oncology 2 hrs/year

2001 – Present

Medical Director of University of Maryland Dosimetry School (one of six certified programs in the country) 2-4 hrs/month

2004 - 2008

Question Writer for National In-Service exam for Radiation Oncology Residents in Training Exam (head and neck cancer section)

2010

Oral Board Examiner - Invited. American Board of Radiology (Head & Neck Cancer Section)

MEDICAL STUDENT MENTORSHIP MEDICAL STUDENTS

CLASS

RESIDENCY PROGRAM

Michael Garofalo Joseph Herman Zach Fowler Selma Jabbour Vladimir Ioffe Suneel Nada Igor Poltinnkov Josh Petit Anil Dhople Ashish Patel Todd Flannery Steven Ronson Pinaki Dutta Suzannah Yavino Jerry Jaboin

1999 2000 2000 2001 2001 2001 2001 2002 2002 2003 2003 2004 2004 2005 2005

University of Chicago University of Michigan Emory University Johns Hopkins Hospital Eastern Virginia Medical School Rush Presbyterian Thomas Jefferson Medical College Massachusetts General Hospital University of Maryland Medical System Thomas Jefferson Medical College University of Maryland Medical System Loma Linda University University of Pennsylvania University of Maryland Medical System Vanderbilt University

6


Total time dedicated to direct teaching activities – 20-25% effort. NATIONAL CLINICAL RESEARCH 1995 – Present

Committee Member, Radiation Oncology Cancer and Leukemia Group B (CALGB) National Cooperative Study Group. Sponsored by The National Cancer Institute.

1996 – Present

Principal Investigator University of Maryland School of Medicine (Full Member Institution), Radiation Oncology Therapy Group (RTOG) National Cooperative Study Group. Sponsored by the National Cancer Institute. (Funding: $75-100,000/year) Status: Ongoing

1998 – Present

Principal Investigator (Radiation Oncologist) The Stents and Radiation Therapy Trial (START). Forty-center, National Registry Trial Evaluating the Use of Brachytherapy for In-Stent Coronary Artery Restenosis. Sponsored by the Novoste Corporation. Funding: $120,000 total cost Study: Study closed.

1998 – Present

University of Maryland Physician Representative Elekta Oncology International Research Corsortium

1999 – Present

Patterns of Care Study Esophageal Cancer Committee Member; Review Committee studying National Standards of Radiotherapy Practice for Esophageal Cancer. Sponsored by the American College of Radiology and the National Cancer Institute. Funding: $60,000 total cost Status: Study closed.

1999 – Present

Principal Investigator (Radiation Oncologist) Stents and Radiation Therapy Trial (START 40) 50 Center National Collaborative Trial Evaluating the use of a 40 mm Source Train in the Management of In-Stent Coronary Artery Restenosis. Sponsored by the Novoste Corporation.

2001 – Present

Thoracic Malignancies Steering Committee, Radiation Therapy Oncology Group Gastrointestinal Disease Site Steering Committee, Radiation Therapy Oncology Group.

2002 – Present

Patterns of Care Study Representative to the American College of Surgeons for the Joint Evaluation of National Standards of Practice for Esophageal Cancer. Sponsored by the National Cancer Institute.

2003 – Present

Principal Investigator RTOG L-0229 A Phase II Trial of Neoadjuvant Therapy with Concurrent Chemotherapy and High Dose Radiotherapy Followed by Surgical Resection, and Consolidative Therapy for Locally Advanced Non-Small Cell Lung Carcinoma. Multi-Institutional, Phase II Trial Status: Opened 10/04

2003 – Present

Vice Chairman, Radiation Therapy Oncology Group Member of the Executive Steering Committee of Radiation Therapy Oncology Group Chairman, Membership Committee, Radiation Therapy Oncology Group NCI Grant No. CA 21661 (5% effort with support).

7


NATIONAL CLINICAL RESEARCH – Continued 2004 - Present

Head and Neck Malignancies Steering Committee, Radiation Therapy Oncology Group.

2004 – Present

Principal Investigator RTOG 0436 A Phase III Trial Evaluating the Addition of Cetuximab to Weekly Paclitaxel, Cisplatin, and Daily Radiation for Patients with Locally Advanced Esophageal Cancer. Multi-Institutional, Phase III Randomized Trial Status: Open 7/2008, accruing patients

2007

Co-Investigator NIH RO1 Grant Feedback Control of Respiration Induced Tumor Motion with a Treatment Couch This study will determine the feasibility of a real-time respiration induced tumor Motion-synchronized treatment couch that will negate the displacement of the tumor during radiation delivery and the development and testing of an inferential model to predict the location of the tumor as a function of the respiration cycle. Funding: $1,416,175, 1% effort on this grant.

2007

Co-Investigator NIH R21 Grant Feedback Control and Inferential Modeling for Radiotherapy Treatment Couch This study has enabled the design and development of the prototype treatment couch and it has determined the dosimetric feasibility of controlling tumor motion by moving the couch in three dimensions. Funding: $273,194, 1% effort on this grant.

INVESTIGATOR INITIATED CLINICAL RESEARCH PROTOCOLS 1996 Principal Investigator: The Role of Tirapazamine (SR4233) in Radiotherapy. New Investigator Award/Intramural Award; University of Maryland School of Medicine. Funding: $15,000 1998 Institutional Principal Investigator: Novoste sponsored BetaCath Trial of Intravascular Radiation to Prevent Coronary Artery Restenosis. Funding: $80,000 total cost Status: Study closed, accrual complete 1998 Institutional Principal Investigator: Stent or Radiation Therapy Intervention for Esophageal Cancer Dysphasia (SORTIE) Plan, Multi-Center Trial Comparing Stents Versus External Beam Radiation for Palliation in Esophageal Cancer Patients. Sponsored by Boston Scientific. Funding: $20,000 total cost Status: Study closed, accrual complete 1999 (IRB #0799205) Principal Investigator: Phase I/II Feasibility Study of Intensity Modulated Radiation Therapy for Newly Diagnosed Cancer Patients. Sponsored by Elekta Corporation. Funding: $20,000 Status: Study closed, accrual complete 1999 Principal Investigator: A Phase I Study of UFT and Hydroxyurea Plus Hyperfractionated Reirradiation Therapy for Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck. Sponsored by Bristol-Myers Squibb. Funding: $60,000

8


Status: Study Closed, accrual complete INVESTIGATOR INITIATED CLINICAL RESEARCH PROTOCOLS - Continued 1999 (GCC #98-39) Principal Investigator: A Phase I Study of Paclitaxel, UFT, Leucovorin and Radiation Therapy for Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck. Sponsored by Roche Pharmaceuticals. Funding: $60,000 Status: Study closed, accrual complete 2000 (GCC #99-67) Principal Investigator: Cisplatin, 5-FU and Accelerated Hyperfractionation with a Concomitant Boost Followed by Surgical Resection then Docetaxel Chemotherapy for Patients Presenting with Locally Advanced Esophageal Carcinoma. Sponsored by Adventis Pharmaceuticals. Funding: $250,000 Status: Study closed, accrual complete 2000 (GCC #00-67) Institutional Principal Investigator: A Multinational, Multicenter, Double-Blind, Placebo Controlled, Randomized, Phase III, Clinical Trial to Determine the Efficacy and Safety of IB-367 Rinse in Reducing the Severity of Oral Mucositis in Patients Receiving Radiotherapy for Head and Neck Malignancies. Sponsored by Intrabiotics Corporation. Funding: $20,000 Status: Closed. 2000 Principal Investigator: The Predictive Value of Thymidylate Synthase, Thymidine Phosphorylase, and Dihydropyrimidine Dehydrogenase in Chemoradiation Strategies for Squamous Cell Carcinoma of the Head and Neck. Sponsored by Roche Pharmaceuticals. Funding: $142,000 2001 (GCC #00-14) Principal Investigator: A Phase I Study of Docetaxel, Carboplatin, and Accelerated Fractionation with Concomitant Boost Radiation Therapy for Patients with Advanced Loco-Regional Squamous Cell Carcinomas of the Head and Neck. Sponsored by Adventis Pharmaceuticals. Funding: $64,500 direct costs Status: Study closed to accrual. 2002 (GCC #02-02) Principal Investigator: A Single Site Evaluation of Amifostine for Mucosal and Hermopoetic Protection, and Concurrent Carboplatin, Paclitaxel and Radiotherapy in the Management of Patients with Advanced Loco-Regional Squamous Cell Carcinomas of the Head and Neck. Sponsored by Medimmune, Inc. Funding: $68,700 direct costs Status: Study closed, accrual complete. 2003 Principal Investigator: Non-Operative Therapy of Local Regional Carcinoma of the Esophagus. A Phase II Study of Paclitaxel, Carboplatin and Radiotherapy. Sponsored by Bristol-Myers Squibb Oncology. Funding: $123,750 total costs Status: Study closed 2004 (GCC #04-43) Co-Principal Investigator: Cetuximab, Paclitaxel, Carboplatin and Radiation for Esophageal Gastroesophageal Junction and Gastric Cancer Multicenter Trial Including, Brown University, and University of Maryland. Sponsored by Bristol-Myers Squibb Oncology. Funding: $250,000 total costs Status: Study closed; accrual complete. 2004 – Present (GCC #04-42) Principal Investigator: A Phase II Study of Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel and Radiotherapy in the Management of Patients with Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck. Sponsored by Bristol-Myers Squibb Oncology.

9


Funding: $302,709 total costs Status: Study open, accruing patients. INVESTIGATOR INITIATED CLINICAL RESEARCH PROTOCOLS - Continued 2008 – (GCC #07-40) Principal Investigator: Neoadjuvant Paclitaxel Poliglumex (PPX;CT-2103), Cisplatin and Radiation for Esophageal Cancer: Multicenter Trial including Brown University and University of Maryland. Sponsored by Cell Therapeutics, Inc. Funding: $100,754 total costs Status: Open, accruing patients 2009 – (NIH-R01) Co-principal Investigator: Radiotherapy with Dose-Rate Regulated Tracking Total funding requested: $1,595,674 PUBLICATIONS – JOURNAL ARTICLES 1. Galkin, B., Feig, S., Mieur H., Suntharalingam, M. Photomicrographics of Breast Calcification Correlation with Histopathological Diagnosis. Radiographics, 3:3, 450-477, 1985. 2. Espinoza-Jacobs, M., Suntharalingam, M., et al. Combined Carbo Platinum CBDCA-Bleomycin (BLEO) and Conventional Radiotherapy for Advanced Unresectable Squamous Cell Carcinoma of the Head and Neck, American Journal of Clinical Oncology, 18:1, 52-55, 1995. 3. Suntharalingam, M., Rudoltz, M.S., Mendenhall, W.H., Parsons, J.T., Stringer, S.P., Million, R.R. The Role of Radiotherapy in the Management of Merkel Cell Carcinoma of the Skin on the Head and Neck. Head and Neck, 17, 96-101, 1995. 4. Rhee, J.G., Eddy, H.A., Hong, J.J., Suntharalingam, M., Vaupel, P.W. Divergent Changes of Diameter and Flow through Individual Blood Vessels Upon Localized Heating. Int. J. Hyperthermia, 12:6, 757-769, 1996. 5. Um, K., Cheston, S., Suntharalingam, M., Rhee, J. Reduced Adriamycin Cytotoxicity in RIF-1 MultiCell Spheroid Due to an Acidic Microenvironment. Environmental Mutagens and Carcinogins. 17:1, 7-11, 1997. 6. Conley, B., Jacobs, M., Suntharalingam, M., Zacharski, D., Ord, R., Gray, W., Aisner, J. The Role of Paclitaxel/Carboplatin and Concurrent Radiotherapy in Unresectable Squamous Cell Carcinoma of the Head and Neck. Seminars in Radiation Oncology. 7:2, Supp (1), 139-141, 1997. 7. Conley, B., Jacobs, M., Suntharalingam, M., Zacharski, D., Ord, R., Gray, W., Aisner, J. A Pilot Trial of Paclitaxel, Carboplatin and Concurrent Radiotherapy for Unresectable Squamous Cell Carcinoma of the Head and Neck. Seminars in Oncology, 24:1, Supp. (2), 787-780, 1997. 8. Sonett, J., Krasna, M., Suntharalingam, M., Doyle, A., Scheutz, J., McLaughlin, J. Interior Trap-Door Surgical Approach for Advanced Stage Lung Cancer Following Neoadjuvant Chemotherapy and Radiotherapy. Penn Assoc Thor Surg, 6, 51-55, 1998. 9. Rhee, J., Liu, J., Suntharalingam, M. Halo Comet Assay Triage of Irradiated Personnel. Armed Forces Radiobiology Research Institute, D5-9, 1998. 10. Sonett, J.R., Krasna, M.J., Suntharalingam, M., Scheutz, J., Gamliel, Z., McLaughlin, J. Safe Pulmonary Resection After Chemotherapy and High Dose Thoracic Radiation. Annals of Thoracic Surgery, 68, 316-320, 1999. 11. Krasna, M.J., Mao, Y.S., Sonett, J.R., Tamura, G., Jones, R., Suntharalingam, M., Meltzer, S.F. P53 Gene Protein Expression Predicts Response and Survival in Esophageal Cancer Patients Treated by Tri-Modality Therapy. Annals of Thoracic Surgery, 68, 2021-2025, 1999.

10


PUBLICATIONS – JOURNAL ARTICLES – Continued 12. Li, X.A., Wang, R, Yu C, Suntharalingam, M. Beta versus Gamma for Catheter-Based Intravascular Brachytherapy: Dosimetric Perspectives in the Presence of Metallic Stents and Calcified Plaques. Int. J. Radiation Oncology, Biol. Phys. 46,4: 1043-1049, 2000. 13. Suntharalingam, M, Haas, M, Conley, BA, Egorin, MJ, Levy, SG, Herman JM, Jacobs, MC, Gray, WC, Ord, RA, Aisner, J, Van Echo, DA. Radiation Therapy with Concurrent Weekly, Carboplatin and Paclitaxel in Advanced Stage Unresectable Squamous Cell Carcinomas of the Head and Neck. Int. J. Radiat Oncol Biol Phys, 47(1):49-56, 2000. 14. Suntharalingam, M, Sonett JR, Haas ML, Doyle LA, Hausner, PF, Schuetz J, Krasna MJ. The Use of Concurrent Chemotherapy with High Dose Radiation Prior to Surgical Resection in Patients Presenting with Apical Sulcus Tumors. The Cancer Journal of the Scientific American, 6,6:365-371. 2000. 15. Suntharalingam, M. Radiation Therapy for Esophageal Cancer. Chest Surgery Clinics of North America, 10:3, 569-581, 2000. 16. Suntharalingam, M. , Haas, M.L., Van Echo, D.A., Haddad, R., Jacobs, M.C., Levy, S., Gray, W.C.., Ord, R.A., Conley, B.A. Predictors of Response and Survival Following Concurrent Chemotherapy and Radiation for Locally Advanced Squamous Cell Carcinomas of the Head and Neck Cancer, 91, 448-554, 2001. 17. Lee, Y.C., Chen, J.C., Amoscato, A.A., Bennouna, J., Spitz, D.R., Suntharalingam, M., Rhee, J.G. Protective Role of BCL-2 in Metabolic Oxidative Stress-Induced Cell Death. J of Cell Science, 114:4, 677-684, 2001. 18. Li, X.A., Suntharalingam, M. Dosimetry of Source Stepping for Intravascular Brachytherapy. Cardiovasc Radiat Med, 2:3, 165-172, 2001. 19. Suntharalingam, M., Haas, M., Sonett, J., Doyle, L.A., Hausner, P.F., Schuetz, J., Greenwald,B., Krasna, M.J. Accurate Lymph Node Assessment Prior to Trimodality Therapy for Esophageal Carcinoma. The Cancer Journal of the Scientific American, 7(6), 509-511, 2001. 20. Suntharalingam, M. Innovations in the Radiotherapy of Head and Neck Cancer, Veterans Health System Journal, 6:3, 54-58, 2001. 21. Jiao, X., Krasna, M.J., Sonett, J., Gamliel, Z., Suntharalingam, M., Doyle, A., Greenwald, B. PreTreatment Surgical Lymph Node Staging Predicts Results of Trimodality Therapy in Esophageal Cancer. European J of Cardio-Thoracic Surgery, 19, 880-886, 2001. 22. Ma, L., Yu, C.X., Earl, M., Holmes, T., Safaraz, M., Li, X.A., Shepard, D., Amin, P.A., DiBiase, S., Suntharalingam, M., Mansfield, C.M. Optimized Intensity Modulated Arc Therapy for Prostate Cancer. Int J Cancer, 96, 379-384, 2001. 23. Li, B., Yu, J., Suntharalingam, M., Kennedy, A.S., Amin, P.A, Chen, Z., Yin, R., Guo, S., Han T., Wang, Y, Yu, N., Song, G., Wong, L. Comparison of Three Treatment Options for Single Brain Metastasis from Lung Cancer. Int J Cancer, 90:1, 37-45, 2002. 24. Jiao, X., Sonett, J., Gamliel, Z., Doyle, A., Schuetz, J., Greenwald, B., Suntharalingam, M., Krasna, M.J. Trimodality Treatment versus Surgery Alone for Esophageal Cancer. A Stratified Analysis with Minimally Invasive Pretreatment Staging. J of Cardiovascular Surgery, 43(4) 531-7, August 2002.

11


25. Song, J.J. Rhee, J.G., Suntharalingam, M., Walsh, S.A., Spitz, D.R., Lee, Y.J. Role of Glutaredoxin in Notabolic Oxidative Stress. Glutaredoxin as a Sensor of Oxidative Stress Medicated by H 202. Journal of Biochemistry, 277 (48); 465-75, November 2002. PUBLICATIONS – JOURNAL ARTICLES – Continued 26. Yu, X.A., Li, A.X., Ma, L., Chen, D., Naqvi, S., Shepard, D., Safaraz, M., Holmes, T., Suntharalingam, M., Mansfield, C.M. Clinical Implementation of Intensity Modulated Arc Therapy. International Journal of Radiation Oncology, Biology and Physics, 53:2, 453-463, 2002. 27. Suntharalingam, M., Laskey, W., Lansky, A.J., Waksman, R., White, L., Teirstien, P., Massulio, Va., Rutherford, B., Elman, A., Kuntz, R.E., Popma, J.J., Bonan, R. START 40 Investigators. Clinical and Angiographic Outcomes After Use of 90Strontium/90Yttrium Beta Radiation for the Treatment of InStent Restenosis: Results from the Stents and Radiation Therapy 40(START 40) Registry. International Journal of Radiation Oncology, Biology and Physics, 52:4, 1075-1082, 2002. 28. Popma, J.J., Suntharalingam, M., Lansky, A.J., Heuser, R.R., Speiser, B., Teirstrein, P.S., Massullo, V., Bass, T., Henderson, R., Silber, S., von Rottkay, P., Bonan, R., Ho, K.H.K, Kuntz, R. A Randomized Trial of 90Strontium/90Yttrium Beta Radiation Versus Placebo Control for the Treatment of In-Stent Restenosis. Circulation, 106:9, 1090-1096, 2002. 29. Morino, Y., Kaneda, H., Fox, T., Takagi, A., Hassan, H.M., Honda, Y., Bonan, R., Crocker, I., Lansky, A.J., Laskey, W.K., Suntharalingam, M., Bonneau, H.N., Yock, P.G., Fitzgerald, P.J. Delivered Dose and Vascular Response Following Beta Radiation for In-Stent Restenosis: Retrospective Dosimetry and Volumetric Intravascular Ultrasound Analysis. Circulation, 106:18, 2334-2339, 2002. 30. Li, X.A., Chilbani, O., Greenwald, B., Suntharalingam, M. Radiotherapy Dose Pertubation of Metallic Esophageal Stents. International Journal of Radiation Oncology, Biology and Physics, 54:4, 12761285, 2002. 31. Mao, Y.S., Suntharalingam, M., Krasna, M.J. Management of Late Distant Metastases After Trimodality Therapy for Esophageal Cancer. The Annals of Thoracic Surgery, 76:5, 1742-1743, 2003. 32. Suntharalingam, M., Laskey, W.K., Tan, J., Kuntz, R., Bonan, R. Vascular Brachytherapy Using A Beta Emitter in Diabetic Patients with In-Stent Restenosis: Angiographic and Clinical Outcomes. International Journal of Radiation Oncology, Biology and Physics, 57:2, 536-542, October 2003. 33. Suntharalingam, M., Moughan, J., Cola, L.R., Krasna, M.J., Kachnic, L., Haller, D.G., Willet, C.G., John, M.J., Minksy, B.D., Owens, J.B. The National Practice for Patients Receiving Radiation Therapy for Carcinoma of the Esophagus: Results of the 1996-1999 Patterns of Care Study. International Journal of Radiation Oncology, Biology and Physics, 56:4, 981-987, 2003. 34. Timmerman, R., Papiez, L., Suntharalingam, M. Extracranial Stereotactic Radiation Delivery: Expansion of Technology beyond the Brain. Technology in Cancer Research and Treatment, 2:2, 153-160, 2003. 35. Edelman, J.J., Suntharalingam, M., Krasna, J.J. The Management of the Patient Undergoing Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer. Current Treatment Options in Oncology, Vol. 4(1), pp 45-53, February 2003. 36. Flannery, T.A., Suntharalingam, M., Kwok, Y., Koffman, B.H., Amin, P.A., Chin, L.S., Nichol, B., Fowler, B., Young, B., Regine, W.F. Gamma Knife Stereotactic Radiosurgery for Synchronous Versus Metachronous Solitary Brain Metastases from Non-Small Cell Lung Cancer. Lung Cancer, 32:3, 327-333, December 2003. 37. Rhee, J.G., Li, D., Guo, M., O’Malley Jr., B.W, Suntharalingam, M. Combination Radiation and

12


Adenovirus Mediated p16 (INK4A) in a Murine Model for Head and Neck Cancer. Journal of ORL, 65:3, 144-154, June 2003. PUBLICATIONS – JOURNAL ARTICLES – Continued 38. O’Malley Jr, B.W., Li, D., Carney, J., Rhee, J., Suntharalingam, M. Molecular Disruption of the MRN(95) Complex Induces Radiation Sensitivity in Head and Neck Cancer. Laryngoscope, 13:9, 1588-1594, September 2003. 39. Brady, D., Yu, S.Z., Koprowski, H., Rhee, J., Kuman, S., Pericle, F., Suntharalingam, M., Van Echo, D.A., Li, D., O’Malley Jr., B.W. Combination Non-Viral Interleukin-2 Gene Therapy and External Beam Radiation Therapy for Head and Neck Cancer. Archives of Otolaryngol Head and Neck, 129:6, 618-622, June 2003. 40. Suntharalingam, M. The Role of Concurrent Chemotherapy and Radiation in the Management of Patients with Squamous Cell Carcinomas of the Head and Neck. Seminars in Oncology, 30:4, Suppl (9), 37-45, August 2003. 41. Suntharalingam, M., Jaboin, J, Taylor, R., Wolf, J., Bangalore, M., Van Echo, D., Ord, R. The Evaluation of Amifostine for Mucosal Protection in Patients with Advanced Lco-Regional Squamous Cell Carcinomas of the Head and Neck (SCCHN) Treated with Concurrent Weekly Carboplatin, Paclitaxel and Daily Radiotherapy (RT). Seminars in Oncology, 31 (6 Suppl 18), 2-7, December 2004 42. Sonett, J.R., Suntharalingam, M., Edelman, M.J., Gamliel, Z., Doyle, A., Hausner, P., Dickerson, A., Krasna, M.J. Pulmonary Resection Following Neoadjuvant High Dose Curative Intent Radiotherapy (>59Gy) and Concurrent Chemotherapy. The Annals of Thoracic Surgery, 78:4, 1200-1205, October 2004. 43. Patel, A.B., Edelman, M.J., Kwok, Y., Krasna, M.J., Suntharalingam, M. Predictors of Acute Esophagitis in Patients with Non-Small Cell Lung Carcinoma Treated with Concurrent Chemotherapy and Hyperfractionated Radiation Therapy Followed by Surgery. The International Journal of Radiation Oncology, Biology and Physics, (60) 4:1106-1112, 2004. 44. Silber, S., Popma, J.J., Suntharalingam, M., Lansky, A.J., Heuser, R.R., Spieser, B., Teirstein, P.S., Bass, T., O’Neill, W., Lasala, J., Reisman, M., Sharma, S.K., Kuntz, R.E., Bonan, R. Two-Year Clinical Follow-Up of 90 Sr/90 Y Beta Radiation Versus Placebo Control for the Treatment of In-Stent Restenosis. The American Heart Journal, 149: 689-694, 2005. 45. Yovino, S., Kwok, Y., Krasna, MJ., Bangalore, M., Suntharalingam, M., An association between preoperative anemia and decreased survival in early-stage non-small-cell lung cancer patients treated with surgery alone. Int J Radiat Oncol Biol Phys, 62(5), 1438-43, August 2005. 46. Kwong, K., Cooper, L., Edelman, M.J., Gamliel, Z., Suntharalingam, M., Burrows, W., Hausner, P., Doyle, L.A., Krasna, M.J. High-Dose Radiation in tri-Modality Treatment of Pancoast tumors Results in High Pathologic Complete Response Rates and Excellent Long-term Survival. The Journal of Thoracic and Cardiovascular Surgery, 29 (6) 1250-7, June 2005. 47. Suntharalingam, M., Moughan, J., Coia, L.R., Krasna, M.J., Kachnic, L., Haller, D.G., Willett, C.G., John, M.J., Minsky, B.D., Owen, J. Outcome Results of the 1996-1999 Patterns of Care Survey of the National Practice for Patients Receiving Radiation Therapy for Carcinoma of the Esophagus. J of Clinical Oncology, 20, 10:2325-2331, 2005. 48. Li, XA, O’Neill, M., Suntharalingam, M. Improving patient-specific dosimetry for intravascular brachytherapy. Brachytherapy, 4: 291-97, 2005. 49. Hamilton, JP, Sato F, Greenwald BD, Suntharalingam, M., Krasna, MJ, Edelman, MJ, Doyle, A.,

13


Berki, AT, Mori, Y., Kan, T., Mantzur, C., Paun, B., Wang, S., Ito, T., Jin, Z., Meltzer, SJ. Promoter methylation and response to chemotherapy and radiation in esophageal cancer. Clin. Gastroenterol Hepatol, Epub, May 2006, Vol 4(6); page 701-708, June 2006. PUBLICATIONS – JOURNAL ARTICLES – Continued 50. Bangalore, M., Matthews, S., Suntharalingam, M. Recent Advances in Radiation Therapy for Head and Neck Cancer. Journal for Otorhinolaryngology, November 2007. 51. Balcer-Kubiczek, E., Attarpour, M., Jiang, J., Kennedy, AS, Suntharalingam, M. Cytotoxicity of Docetaxel (Taxotere) used as a Single Agent and in Combination with Radiation in Human Gastric, Cervical and Pancreatic Cancer Cells. Chemotherapy, 52:231-240, 2006. 52. Suntharalingam, M. Definitive chemoradiation in the management of locally advanced esophageal cancer. Seminars in Oncology, 17(1), 22-28, January 2007. 53. D’Souza, WD., Nazareth, DP., Zhang, B., DeYoung, C., Suntharalingam, M., Kwok, Y., Yu, CX., Regine, WF. The use of gated and 4d CT imaging in planning for stereotactic body radiation therapy. Med Dosim., Vol. 32(2), pp 92-101, June 2007. 54. Safran, H., Suntharalingam, M., Dipetrillo, T., Ng, T., Doyle, LA, Krasna, MJ, Plette, A., Evans, D., Wanebo, H., Akerman, P., Spector, J., Kennedy, N., Kennedy, T. Cetuximab with Concurrent Chemoradiation for Esophagogastric Cancer: Assessment of Toxicity. Int J Radiat Oncol Phys., November 2007. 55. Rhee, JG, LI, D., Suntharalingam, M., Guo, C., O’Malley, BW, Carney, JP. Radiosensitization of head/neck squamous cell carcinoma by adenovirus-mediated expression of the Nbs 1 protein. Int J Radiation Oncol Biol Phys, 67(1), 273-78, January 2007. 56. Machtay, M., Pajak, TF, Suntharalingam, M., Shenouda, G., Hershock, D., Stripp, DC, Cmelak, AJ., Schulsinger, A., Fu, KK. Radiotherapy with or without Erythropoietin for Anemic Patients with Head and Neck Cancer: A Randomized Trial of the Radiation therapy Oncology Group (RTOG 99-03). Int J Radiat Oncol Biol Phys, 69(4) 1008-1017, October 2007. 57. D’Souza, WD, Nazareth, DP, Zhang, B., DeYoung, C., Suntharalingam, M. Kwok, Y., Yu, CX, Regine, WF. The Use of Gated and 4D CT Imaging in Planning for Stereotactic Body Radiation Therapy. Med Dosim, 32(2), 92-101, May 2007. 58. Yovino, S., Settle, K., Taylor, R., Wolf, J., Kwok, Y., Cullen, K., Ord, R., Zimrin, A., Strome, S., Suntharalingam, M. Can Adjuvant Neck Dissection Be Deferred in Patients with Squamous Cell Carcinoma of the Head and Neck Who Obtain A Complete Response to Definitive Chemoradiotherapy. Int. J. Radiation Oncology Biol Phys., Vol. 69(3), pp S15., 2008 59. Safran, H., Suntharalingam, M., DiPetrillo, T., Ng, T., Doyle, LA, Krasna, M., Plette, A., Evans, D., Wanebo, H., Akerman, P., Spector, J., Kennedy, N., Kennedy, T. Cetuximab with Concurrent Chemoradiation for Esophagogastric Cancer: Assessment and Toxicity. Int. J. Radiation Oncology Biol Phys., Vol. 70, No.2, pp 391-395, 2008. 60. Corn, BW., Wexler, ID., Suntharalingam, M., Inbar, M., Curran, WJ., Jr., Radiation Therapy Oncology Group. Globalization of the Radiation Therapy Oncology Group: Implementation of a model for service expansion and public health improvement. J. Clin Oncol, Vol., 26(7), pp 11601166, March 1, 2008. 61. Wu, J., Li, H., Shekhar, R., Suntharalingam, M., D’Souza, W. An evaluation of planning techniques for stereotactic body radiation therapy in lung tumors. Epub. March 2008, Radiother Oncol, Vol 87(1), pp 35-43, April 2008.

14


62. Flannery, T.W., Suntharalingam, M., Regine, W.F., Chin, L.S., Krasna, M.J., Shehata, M.K., Edelman, M.J., Kremer, M., Patchell, R.A., Kwok, Y. Long-Term Survival in Patients with Synchronous, Solitary Brain Metastasis from Non-Small Cell Lung Cancer Treated with Radiosurgery. Int. J. Radiation Oncology Biol Phys., Vol 72(1), pp. 19-23, September 2008. PUBLICATIONS – JOURNAL ARTICLES – Continued 63. Edelman, MJ., Suntharalingam, M., Burrows, W., Kwong, KF., Mitra, N., Gamliel, Z., Riley, M., Cooper, LB., Kennedy, NL, Buskirk, S., Hausner, P., Doyla, LA, Krasna, MJ. Phase I/II Trial of hyperfractionated radiation and chemotherapy followed by surgery in stage III lung cancer. Ann Thoracic Surg., Vol. 86(3), pp 903-910. September 2008. 64. Edelman, MJ, Burrows, W, Krasna, MJ, Suntharalingam, M. Phase I Trial of Carboplatin/Paclitaxel/ Bortezomib and Concurrent Radiotherapy followed by Surgical Resection in Stage III Non-Small Cell Lung Cancer. J of Thoracic Onc. January 2009. 65. Saito, K., Khan, K., Yu, SZ, Ronson, S., Rhee, J., Li, G., Van Echo, D. Suntharalingam, M., O’Malley, BW, Jr., Li, D. The Predictive and Therapeutic Value of Thymidine Phosphorylase and Dihydropyrimidine Dehydrogenase in Capecitabine (Xeloda)-based Chemotherapy for Head and Neck Cancer. Laryngoscope, Vol., 119(1), pp 82-88, January 2009. 66. Patel, S., Macdonald, OK, Suntharalingam, M. Evaluation of the Use of Prophylactic Cranial Irradiation in Small Cell Lung Cancer. Cancer, Vol. 115 (4), pp 842-850, February 2009. 67. Neuner, G., Patel, A., Suntharalingam, M. Chemoradiotherapy for Esophageal Cancer. Gastrointestinal Cancer Research, March/April 2009. 68. Settle, K., Taylor, R., Wolf, J., Young, K. Cullen, K., Carter, K., Ord, R., Zimrin, A., Strome, S., Suntharalingam, M. Race Impacts Outcome in Stage III/IV Squamous Cell Carcinomas of the Head and Neck Following Concurrent Chemoradiation Therapy. Cancer, Vol. 115 (8), pp. 1744-1752, April 15, 2009. 69. Kim, C., Monjazeb, AM, Suntharalingam, M., Giesinger, KR, Blackstock, AW. Preoperative Versus Postoperative Chemoradiotherapy in the Trimodality Management of Esophageal Cancer. Clinical Advances In Hematology & Oncology, Vol. 7 (5) pp. 327-324, May 2009. 70. Yovino, S., Settle, K., Taylor, R., Wolf, J., Kwok, Y., Cullen, K., Ord, R., Zimrin, A., Strome, S., Suntharalingam, M. Phase I Trial of Carbonplating/Paclitaxel/Bortezomib and Concurrent Radiotherapy followed by Surgical Resection in Stage III Non-Small Cell Lung Cancer. Head & Neck, May 2009. 71. Cheng, S., Iannettoni, M., Koshy, M., Suntharalingam, M., Urba, S. Squamous Cell Carcinoma of the Esophagus: Treat With How Many Modalities? Seminars in Oncology, Vol. 36 (6) pp 493-497. 72. Jianzhou, W., Peng, L., Raj, S., Huiling, L., Suntharalingam, M, D’Souza, W. Do Tumors in the lung deform during normal respiration? An image registration investigation. International Journal of Radiation Oncology Biology Physics, Vol. 75(1); pp 268-275. September, 2009. 73. Settle K, Posner MR, Schumaker LM, Tan M, Suntharalingam M, Goloubeva O, Strome SE, Haddad RI, Patel SS, Campbell EV, Sarlis N, Lorch J, Cullen KJ. Racial Survival Disparity in Head and Neck Cancer Results from Low Prevalence of Human Papillomavirus Infection in Black Oropharyngeal Cancer Patients. Cancer Pre Res, Vol. 2(9); 776-81, Sep 2009. 74. Jin, Z., Yi, BY, Lasio, G., Suntharalingam, M, Yu, C. Tomographic image via background subtraction using an x-ray projection image and a priori computed tomography. Medical Physics, Vol. 36(10); 4433-4439, Nov. 2009.

15


75. D’Souza, WD, Malinowski, KT, Van Liew, S, D’Souza, G, Asbury, K., Suntharalingam, M., Regine, WF. Investigation of Motion Sickness and Inertial Stability on a Moving Couch for Intra-Fraction Motion Compensation. Acta Oncologica, Vol. 48(8), pp 1198-1203, November, 2009.

PUBLICATIONS – JOURNAL ARTICLES – Continued 76. Peng HQ, Halsey K, Sun CC, Manucha V., Nugent S., Rodgers WH, Suntharalingam, M. Greenwald BD. Clinical Utility of Postchemoradiation Endoscopic Brush Cytology and Biopsy in Predicting Residual Esophageal adenocarcinoma. Cancer Cytopathol, Vol. 117(6); 463-72. December 25, 2009. 77. Lim, DH, Yi, BY, Mirmiran, A, Dhople, A, Suntharalingam, M. Optimal Beam Arrangement for Stereotactic Body Radiation Therapy Delivery in Lung Tumors. Acta Oncologica, Vol. 49, pp 219224, 2010. 78. Yovino S, Settle K, Taylor R, Wolf J, Kwok Y, Cullen KJ, Ord R, Zimrin A, Strome S, Suntharalingam M. Patterns of Failure Among Patients with Squamous Cell Carcinoma of the Head and Neck who obtain a complete response to chemoradiotherapy. Head & Neck, Vol. 32(1); pp 46-52, January 2010. 79. Krasna MJ, Gamliel Z, Burrows WM, Sonett JR, Kwong KF, Edelman MJ, Hausner PF, Doyle LA, DeYoung C, Suntharalingam, M. Pneumonectomy for Lung Cancer After Preoperative Concurrent Chemotherapy and High-dose Radiation. Ann Thorac Surg, Vol. 89(1); 200-206, January 2010. 80. Koshy M, Goloubeva O, Suntharalingam, M. Impact of Neoadjuvant Radiation on Survival in Stage III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys, Jun, 2010. 81. Koshy M, Greenwald BD, Hausner P, Krasna MJ, Horiba N, Battafarano RJ, Burrows W, Suntharalingam M. Outcomes After Trimodality Therapy for Esophageal Cancer: The Impact of Histology on Failure Patterns. Am J Clin Oncol, Aug 3, 2010. 82. Edelman MJ, Burrows W, Krasna MJ, Bedor M, Smith R, Suntharalingam M. Phase I Trial of carboplatin/paclitaxel/bortezomib and concurrent radiotherapy followed by surgical resection in Stage III non-small cell lung cancer. Lung Cancer, Vol. 68, pgs 84-88, 2010. 83. Rutter CE, Yovino S, Taylor R, Wolf J, Cullen KJ, Ord R, Athas M, Zimrin A, Strome S, Suntharalingam M. Impact of Early Percutaneous Endoscopic Gastrostomy Tube Placement on Nutritional Status and Hospitalization in Patients with Head and Neck Cancer Receiving Definitive Chemoradiation Therapy. Head & Neck, Dec 15, 2010. 84. Dipetrillo T, Suntharalingam M, Ng T, Fontaine J, Horiba N, Oldenburg N, Perez K, Birnbaum A, Battafarno R, Burrows W, Safran H. Neoadjuvant Paclitaxel Poliglumex, Cisplatin, and Radiation for Esophageal Cancer: A Phase 2 Trial. Am J Clin Oncol. Feb 3, 2011. 85. Strongin A, Yovino S, Taylor R, Wolf J, Cullen K, Zimrin A, Strome S, Regine W, Suntharalingam M. Primary Tumor Volume is an Important Predictor of Clinical Outcomes Among Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck Treated with Definitive Chemoradiotherapy. Int J Radiat Oncol Biol Phys. May 5, 2011. 86. Patel S, Macdonald OK, Nagda S, Bittner N, Suntharalingam, M. Evaluation of the Role of Radiation Therapy in the Management of Malignant Thymoma. Int J Radiat Oncol Biol Phys. May 17, 2011, [Epub ahead of print]. 87. Suntharalingam M, Kwok J, Goloubeva O, Parekh A, Taylor R, Wolf J, Zimrin A, Strome S, Ord R, Cullen KJ. Phase II Study Evaluating the Addition of Cextuximab to the Concurrent Delivery of

16


Weekly Carboplatin, Paclitaxel, and Daily Radiotherapy for Patients with Locally Advanced Squamous Cell Carcinomas of the Head and Neck. Int J Radiat Oncol Biol Phys. May 19, 2011 [Epub ahead of print].

PUBLICATIONS – JOURNAL ARTICLES – Continued 88. Mahmood U, Koshy M, Goloubeva O, Suntharalingam M. Adjuvant Radiation Therapy for HighGrade and/or Locally Advanced Major Salivary Gland Tumors. Arch Otolaryngol Head Neck Surg, 137(10); 1025-1030. October, 2011. 89. Tan S, Kligerman S, Chen W, Lu M, Kim G, Feigenberg SJ, D’Souza WD, Suntharalingam, M. Spatial-Temporal FDG-PET Features for Predicting Pathologic Response of Esophageal Cancer to Neoadjuvant Chemoradiotherapy. Int J Radiat Oncol Biol Phys, 2012. 90. Suntharalingam, M, Paulus R, Edelman MJ, Krasna M, Burrows W, Gore E, Wilson LD, Choy H. Radiation Therapy Oncology Group Protocol 02-29: A Phase II Trial of Neoadjuvant Therapy with Concurrent chemotherapy Full-Dose Radiation Therapy Followed by Surgical Resection Consolidative Therapy for Locally Advanced Non-small Cell Carcinoma of the Lung. Int J Radiat Oncol Biol Phys, Vol. 84, 2, pgs 456-463, October, 2012. 91. Vosken CJ, Sewell D, Hertzano R, DeSanto J, Rollins S, Lee M, Taylor R, Wolf J, Suntharalingam M, Gastman B, Papadimitriou JC, Lu C, Tan M, Morales R, Cullen K, Celis E, Mann D, Strome SE. Induction of MAGE-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma. Head Neck, Vol. 34(12), pp 1734-1746, December, 2012. 92. Howell, DD, James, JL, Hartsell, WF, Suntharalingam, M, Machtay, M, Suh, JH, Demas, WF, Sandler, HM, Kachnic LA, Berk, LB. Single-Fraction Radiotherapy Versus Multifraction Radiotherapy for Palliation of Painful Vertebral Bone Metastases – Equivalent efficacy, Less Toxicity, More Convenient. Cancer, Vol 119, pgs 888-896, February, 2013. 93. Beutel G, Perthel R, Suntharalingam M, Bode-Boger SM, Martens-Lobenhoffer J, Kielstein JT, Kielstein H. Effect of Chronic Elevated Asymmetric Dimethylarginine (ADMA) levels on Granulopoiesis. Ann Hematol, Vol. 92(4) 505-508, April 2013. 94. Zhang H, Tan S, Chen W, Kligerman, S, Kim, G, D’Souza, WD, Suntharalingam, M. Modeling Pathologic Response of Esophageal Cancer to Chemoradiation Therapy Using Spatial-Temporal 18FFDG PET Features, Clinical Parameters, and Demographics. Int J Radiat Oncol Biol Phys, Sept. 2013. 95. Zhang H, Tan S, Chen W, Kligerman S, Kim G, D’Souza WD, Suntharalingam M, Lu W. Modeling Pathologic Response of Esophageal Cancer to Chemoradiation Therapy Using Spatial-Temporal (18) F-FDG PET Features, Clinical Parameters, and Demographics. Int J Radiat Oncol Biol Physics. Vol. 88(1) 195-203, Jan, 2014. 96. Kim GJ, Koshy M, Hanlon AL, Horiba MN, Edelman MJ, Burrows, WM, Battafarano RJ, Suntharalingam M. The Benefit of Chemotherapy in Esophageal Cancer Patients with Residual Disease After Trimodality Therapy. Am J Clin Oncol. Jan, 2014 [Epub ahead of print] BOOK CHAPTERS 1. Salazar, O.M., Suntharalingam, M. Palliative Radiation for Widespread Pulmonary Disease in Medical Radiology in Kagan R., Steckel, R., (eds), Practical Approaches to Cancer Invasion and Metastasis. Springer Verlag, 1994.

17


2. Suntharalingam, M. Principles and Complications of Radiation Therapy in Ord, R.A and Blanchart, R.H. (eds), Oral Cancer: The Dentist’s Role in Diagnosis, Management, Rehabilitation and Prevention. Quintessence Publishing, 1999.

BOOK CHAPTERS - Continued 3. Paz, I.B., Suntharalingam, M., Leichman, L. Esophageal Cancer in Pazdur, R., Coia, L.R., Hoskins, W.J., Wagman, L.D. (eds), Cancer Management: A Multidisciplinary Approach. Medical, Surgical and Radiation Oncology, 5th Edition, PRR Inc, 2001. 4. Paz, I.B., Suntharalingam, M., Hwang, J.J., Marshall, J.L., Leichman, L. Esophageal Cancer in Pazdur, R., Coia, L.R., Hoskins, W.J., Wagman, L.D. (eds), Cancer Management: A Multidisciplinary Approach. Medical, Surgical and Radiation Oncology, 5 th Edition, PRR Inc., 2002. 5. Moore-Higgins, G.J., Strohl, R.A., Suntharalingam, M. Lung Cancer, in Bruner, D.W., MooreHiggins, G.J., Haas, M. (eds), Outcomes in Radiation Therapy. Multidisciplinary Management, 2001. 6. Paz, I.B., Suntharalingam, M., Hwang, J.J., Marshall, J.L., Leichman, L. Esophageal Cancer in Pazdur, R., Coia, L.R., Hoskins, W.J., Wagman, L.D. (eds), Cancer Management: A Multidisciplinary Approach. Medical, Surgical and Radiation Oncology, 8 th Edition, PRR Inc., 2003. 7. Paz, I.B., Hwang, J.J., Marshall, J.L., Leichman, L., Suntharalingam, M. Esophageal Cancer in Pazdur, R., Coia, L.R., Hoskins, W.J., Wagman, L.D. (eds), Cancer Management: A Multidisciplinary Approach. Medical, Surgical and Radiation Oncology, 8 th Edition, PRR Inc, 2004. 8. Suntharalingam, M, Settle, K., Cullen, K. Perspective on Fractionated Radiation and Chemotherapy for Head and Neck Tumors, Chin, L., Regine, W.F. (eds) in Principles and Practice of Stereotactic Radiosurgery, 1st edition, Springer, 2005. 9. Patel, A.B., Suntharalingam, M. Definitive Radiochemotherapy in Esophageal Tumors: Principles and Practice. Jobe BA, Thomas CR, Hunter JG, Tran N, Editors. Demos Medical Publishing, March 2009. POSTER PRESENTATIONS 1. Suntharalingam, M., Rhee, J., Eddy, H., Salazar, O.M. Reoxygenation Kinetics in RIF-1 Multi-Cell Spheroids Characterized by the Changes in Cytotoxicity of X-Rays and SR-4233, A Hypoxic Cell Toxin. Presented at the American Society for Therapeutic Radiology and Oncology Annual Meeting. San Francisco, CA, October, 1994. 2. Suntharalingam, M., Ampey, L.L. A Radiobiologic Evaluation of Overall Treatment Time in Patients with Early Stage Glottic Carcinoma. Presented at The American Radium Society Annual Meeting. Paris, France, April 29 – May 3, 1995. 3. Moon, S.D.M., Suntharalingam, M., Liu, J, Rhee, J.G. Reoxygenation Patterns of RIF-1 Multi-Cell Spheroids Determined by Halo and Halo-Comet Assays Following SR-4233 Exposures. Presented at the Radiation Research Society Meeting. Chicago, IL, April, 1996. 4. Rhee, J.G., Lee, K.H., Liu, J., Um, K.I., Vines, E., Suntharalingam, M. A Constant Level of HSP70 During a Transitional Period from a Heat-Sensitive to a Heat-Resistant State Following Dispersion of RIF-1 Spheroids. Presented at the North American Hyperthermia Society Meeting. Providence, RI, May, 1997. 5. Park, S., Suntharalingam, M., Gray, W., Saraf, W., Elias, G. Comparison of Condensed Modality Treatment with Chemotherapy and Radiation Versus Radiation Alone on Patients with Nasopharyngeal Cancer: A Retrospective Review. Presented at the 1997 Annual Meeting of the

18


Society of Head and Neck Surgeons. Cancun, Mexico, April 10-12, 1997. 6. Rhee, J.G., Suntharalingam, M., Mansfield, C.M. Localization of Tirapazamine Induced DNA Damage in RIF-1 Multi-Cell Spheroids; in Situ Alkaline Comet Assay (ISACA). Presented at the Radiation Research Society Meeting. Louisville, KY, May 1998. POSTER PRESENTATIONS - Continued 7. Suntharalingam, M., Conley, B.A., Van Echo, D.A., Jacobs, M.C., Levy, S.G., Li, B., Ord, R.A., Gray, W.C., Aisner, J.A. Evaluation of Response and Survival in Unresectable SCCHN Treated with Chemoradiation on Three Consecutive Institutional Trials. Presented at the First International Chicago Symposium on Malignancies of the Chest, Head and Neck. October 1-2, 1999. 8. Haddad, R.I., Suntharalingam, M., Chen,T., Levy, S., Van Echo, D.E. Pre-Treatment Hemoglobin is Associated with Response to Chemoradiation (CRT) in Patients with Advanced Unresectable Squamous Cell Carcinoma of the Head and Neck. Presented at the American Society of Clinical Oncology Annual Meeting. New Orleans, LA, May 20-23, 2000. 9. Fowler, B.Z., Suntharalingam, M., Koffman, B.H., Nichols, B., Chin, L., Amin, P.A., Young, A.B., Regine, W.F. Gamma Knife Stereotactic Radiosurgery for Synchronous Versus Metachronous Solitary Brain Metastases from Non-Small Cell Lung Cancer. Presented at The American Society of Therapeutic Radiology and Oncology 42nd Annual Meeting. Boston, MA, October 22-26, 2000. 10. Suntharalingam, M., DeYoung, C.M., Edelman, M.J., Greenwald, B., Duckham, E., Krasna, M.J. Concomitant Boost RT as Part of an Induction Regimen Followed by Surgery and Adjuvant Docetaxel for Locally Advanced Esophageal Cancer. Presented at the 38 th Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, May 18-21, 2002. 11. Sullivan, PH, Taylor, R, Ord R, Wolf, J, VanEcho D, Kwok Y, Suntharalingam, M. Long-Term Survival and Functional Quality of Life Assessments in Patients with Locally Advanced Unresectable Squamous Cell Carcinomas of the Head and Neck Treated with Concurrent Chemoradiation, presented at the 45th Annual Meeting of the American Society of Therapeutic Radiology and Oncology, Atlanta, GA, Oct. 3-7, 2004. 12. Yovino S, Kwok Y, Krasna MJ, Bangalore M, Suntharalingam, M. Preoperative Anemia Decreases Survival in Patients with Stage I and II Non-Small Cell Lung Cancer. Presented at the 46 th Annual Meeting of the American Society of Therapeutic Radiology and Oncology, Atlanta, GA, October,2004. 13. Suntharalingam, M., Wolf, J., Taylor, R., Jaboin, J., Bangalore, M., Ord, R., Cullen, K. The Evaluation of Amifostine for Mucosal Protection in Advanced Loco-Regional Squamous Cell Carcinomas of the Head and Neck (SCCHN) Treatment with Concurrent Weekly Carboplatin, Paclitaxel, and Daily Radiotherapy (RT). Presented at the American Society of Therapeutic Radiology and Oncology (ASTRO) 47th Annual Meeting. Denver, CO, October 16-20, 2005. 14. Suntharalingam, M., Paulus, R., Edelman, MJ., Krasna, M., Burrows, W., Gore, E., Yom, SS., Choy, H. A Phase II Trial of Neoadjuvant Therapy with Concurrent Chemotherapy and High Dose Radiotherapy Followed by Surgical Resection and Consolidative Therapy for LA NSCLC. Presented at ASCO Annual Meeting. Chicago, IL., June 2010. NATIONAL PRESENTATIONS – INVITED SPEAKER 1. Radiation Modifiers: From Discovery to Reality: Suntharalingam, M., Salazar, O.M. Presented at the 8th Bicenntial Meeting of Circulo De Radioterapeutas Ibero Latino Americans (CRILA). San Juan, Puerto Rico, May 4-8, 1992.

19


2. Technical Considerations of Ultrasound and Template Guided I125 Implantation for Early Stage Prostate Cancer. Presented at the Mid-Atlantic Society for Radiation Oncology Meeting. Richmond, VA, September 23, 1992.

NATIONAL PRESENTATIONS – INVITED SPEAKER – Continued 3. Organ Preservation in Advanced Larynx Cancer: A Radiation Oncologist’s Perspective. Presented at the Southern Medical Association Annual Meeting. Baltimore, MD, November 22, 1996. 4. Staging and Combined Modality Treatment for Esophageal Cancer Radiation Oncology with TriModality Treatment Panel Discussion. Presented at the Multidisciplinary Treatment of Solid Tumors Conference, Baltimore, MD, September 19-20, 1997. 5. Multidisciplinary Treatment of Solid Tumors Conference. Baltimore, MD, September 19-20, 1997. 6. The University of Maryland Experience with the Beta Cath Trial. Presented at the Novosote European Investigators Meeting. Brussels, Belgium, June 1998. 7. The Use of Radiation Therapy to Prevent Coronary Artery Restenosis. Presented at the Radiation Oncology Ground Rounds, Rush Presbyterian Hospital. Chicago, IL, July 1998. 8. Radiation Therapy with Concurrent Weekly Carboplatin and Paclitaxel in Advanced Stage Unresectable Squamous Cell Carcinomas of the Head and Neck. Presented at the Fox Chase Cancer Center Investigator Workshop. Lanai, HI, March 11-15, 2000. 9. Clinical Implementation of Intensity-Modulated Arc Therapy. Presented at the International Symposium on Intensity-Modulated Radiation Therapy. Jefferson Medical College, Philadelphia, PA, March 17-18, 2000. 10. The Role of Radiation in the Prevention of Vascular Restenosis. Presented at the Device Workshop at the Society of Cardiac Angiography and Interventions Meeting. Charleston, SC, May 4, 2000. 11. The Role of Vascular Brachytherapy in the Prevention of Coronary Artery Restenosis. Presented at the American College of Medical Physicist (ACMP) Annual Meeting. Vancouver, Canada, May 18, 2000. 12. Combining Radiation and Chemotherapy in the Treatment of Head and Neck Carcinomas. Presented at Oncology Ground Rounds, University of Louisville. Louisville, KY, August 17, 2000. 13. The Role of Radiation in the Prevention of Coronary Artery Restenosis. Presented to the Department of Radiation Oncology and Combining Radiation and Chemotherapy in the Treatment of Head and Neck Carcinomas. Presented at Oncology Ground Rounds as Visiting Professor, Department of Radiation Medicine, University of Kentucky. Lexington, KY, August 18, 2000. 14. Advances in the Treatment of Head and Neck Cancer. Presented at Cancer Center Ground Rounds, Divine Providence Hospital. Williamsport, PA, August 29, 2000. 15. Innovations in the Use of Radiotherapy for Head and Neck Cancer. Presented at the 5 th Annual National VA Oncology Symposium. Alexandria, VA, October 5, 2000. 16. Multi-Modality Treatment for Early Stage Head and Neck Carcinomas. Presented at the Bristol-Myers Squibb Oncology Physician Speakers Training Program. Chicago, IL, October 5-7, 2000. 17. Implementation of a Vascular Brachytherapy Program. Presented at the Transcatheter Therapeutics National Meeting. Washington, DC, October 19, 2000.

20


18. IMRT Delivery Approaches and Clinical Experience with IMAT (Intensity Modulated Radiation Therapy). Presented at the Elekta Symposium on Advanced Clinical Solutions in Conformal Radiotherapy (IMRT) and Gamma Knife Surgery, American Society of Therapeutic Radiology and Oncology 42nd Annual Meeting. Boston, MA, October 21, 2000. NATIONAL PRESENTATIONS – INVITED SPEAKER – Continued 19. Moderator - Scientific Session on Coronary Vascular Radiation at the 42 nd Annual Meeting of the American Society for Therapeutic Radiology and Oncology. Boston, MA, October, 30, 2000. 20. Clinical Applications of Intensity-Modulated Radiation Therapy. Presented at the Gulf Coast Oncology Center. Panama City, FL, November 13, 2001. 21. Combined Modality Management of Head and Neck Cancer. Presented at Educational Symposium at the American Society of Therapeutic Radiation and Oncology Annual Meeting. San Francisco, CA, November 4, 2001. 22. Moderator - Endovascular Brachytherapy Scientific Session at the 43 rd Annual Meeting of the Association for Therapeutic Radiology and Oncology. San Francisco, CA, November 7, 2001. 23. The Role of Endovascular Brachytherapy in the Management of In-Stent Restenosis. Presented at the 2001 Scientific Symposium of the Delaware Valley Chapter of the American Association of Physicists in Medicine Meeting, Jefferson Medical College. Philadelphia, PA, December 7, 2001. 24. Co-Moderator - The Annual Simon Kramer Institute Symposium for the Development of a New Staging System for Esophageal Cancer. New Philadelphia, PA, August 25, 2001. 25. The Role of Staging in the Treatment of Esophageal Cancer with Pre-Operative Chemotherapy and Radiation. Presented at the Annual Simon Kramer Institute Symposium for the Development of a New Staging System for Esophageal Cancer. New Philadelphia, PA, August 25, 2001. 26. The University of Maryland Experience with Chemoradiation in Locally Advanced Head and Neck Cancer. Presented at the Fox Chase Cancer Center Investigator Workshop. Kohala, HI, March 2327, 2002. 27. Current Trends in the Management of Locally Advanced Carcinomas of the Head and Neck. Presented at the Carolina Regional Tumor Conference. Raleigh, NC, June 3, 2002. 28. Current Trends in the Management of Locally Advanced Carcinomas of the Head and Neck. Presented at Virginia Regional Cancer Meeting. Virginia Beach, VA, June 4, 2002. 29. The Role of Functional Imaging in Radiation Oncology Research Strategies. Presented at Elekta Users Meeting. Nassau, Bahamas, May 31, 2003. 30. Clinical Implementation of an Intensity-Modulated Radiation Therapy Program. Presented at the Annual Meeting of the Atlanta Oncology Associates. Atlanta, GA, August 23, 2003. 31. The Role of Combined Modality Therapy for Locally Advanced Squamous Cell Carcinomas of the Head and Neck. Presented at Grand Rounds of the Cancer Center at Wake Forest University Medical School. October 3, 2003. 32. Combined Modality Management of Head and Neck Cancer. Presented at Educational Symposium at the American Society of Therapeutic Radiation and Oncology Annual Meeting. Salt Lake City, UT, October 19, 2003. 33. Recent Innovations in Radiation Oncology and Paradigm Changes. Presented at the Washington D.C. Veterans Administration Hospital Medical Grand Rounds. Washington, DC, November 5, 2003.

21


34. Outcome Results of the 1996-1999 Patterns of Care Survey of the National Practice for Patients Receiving Radiation Therapy for Carcinoma of the Esophagus. Presented at the 89 th Annual Meeting of Radiological Society of North America Special Focus Session – ASTRO Invited Papers. December 1, 2003. NATIONAL PRESENTATIONS – INVITED SPEAKER – Continued 35. Clinical Applications of Intensity-Modulated Radiation Therapy. Presented at the University of Colorado Radiation Oncology Grand Rounds. December 15, 2003. 36. The Value of Surgery Following Chemoradiation for Patients with Esophageal Cancer. Presented at the Southern Association of Oncology Annual Meeting. Amelia Island, FL, August 8, 2004. 37. The Role of Tri-Modality in Patients Presenting with Esophageal Cancer. Presented at American Association of Thoracic Surgery Annual Meeting. Toronto, Canada, April 24, 2004. 38. The Use of Concurrent Chemotherapy and Radiation Therapy in the Management of Head and Neck Cancer Patients, Philadelphia Area Radiation Oncology Resident Review, April 28, 2004. Moderator Scientific Session on Coronary and Cerebra-Vascular Radiation. Presented at the 46 th Annual Meeting of the American Society for Therapeutic Radiology and Oncology. Atlanta, GA, October 6, 2004. 39. The Evolving Role of Radiation Therapy in the Management of Head and Neck Cancer, Visiting Professor, Hahnemann School of Medicine, Drexel University, Department of Radiation Oncology. October 28, 2004. 40. Trimodality Therapy in Esophageal Cancer, Visiting Professor, Weill Medical College of Cornell University, Department of Radiation Oncology, May 19, 2005 41. Future Directions in Esophageal Cancer, Visiting Professor, Emory University School of Medicine, March 24, 2005. 42. A Phase II Trial Evaluating the Efficacy of Weekly Cetuximab, Paclitaxol, Carboplatin and Daily RT in Esophageal Cancer. Presented at the 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO). Philadelphia, PA. November 2006. 43. Clinical Utilization of IMRT in Head and Neck Cancer. Panel Discussion, IMRT/Physics/Radiobiology Dose Effect. Presented at the 49th Annual Meeting of the American Society for Therapeutic Radiology and Oncology. Los Angeles, CA., October 2007. 44. Innovations in Head and Neck Radiotherapy, a multidisciplinary discussion. Presented at the annual meeting of the American College of Surgeons 2007, Chicago, IL. 45. The Current Role of Tri-Modality Therapy in Stage III Non-Small Cell Lung Cancer. Moderator -Educational Session. Presented at the 50th Annual Meeting of the American Society for Therapeutic Radiology and Oncology. Boston, MA., September 2008. 46. Challenging Cases in Esophageal and Gastric Cancer. Multi-Disciplinary Panel. Presented at the 2009 Gastrointestinal Cancers Symposium. American Society of Clinical Oncology. San Francisco, CA, January 2009. 47. Neoadjuvant versus Adjuvant Chemotherapy and Radiation for Esophagogastric Cancers: Do the Results of Recent Trials Give us a Direction. Presented at ASCO 2010 Annual Meeting. Chicago, IL., June, 2010. 48. A Phase II Trial of Neoadjuvant Therapy with Concurrent Chemotherapy and Full Dose Radiotherapy (XRT) followed by Resection and Consolidative Therapy for LA-NSCLC. Presented at the 51 st Annual

22


Meeting of the American Society for Therapeutic Radiology and Oncology. San Francisco, CA, November 2010.

LOCAL PRESENTATIONS – INVITED SPEAKER 1. Preliminary Results of I125 Implantation for Early Stage Prostate Cancer: The University of Maryland Experience: Presented at the National Cancer Institute Radiation Oncology Grand Rounds. Bethesda, MD, December 9, 1992. 2. The Use of Radiotherapy in the Management of Early Stage Glottic Carcinoma. Presented at Ground Rounds in the Department of Radiation Oncology, University of Maryland. Baltimore, MD, June 1994. 3. Future Trends in the Management of Esophageal Cancers. Presented at Ground Rounds in the Department of Radiation Oncology, University of Maryland. Baltimore, MD, September 1995. 4. The Emerging Role of Brachytherapy in the Treatment of Cholangiocarcinoma. Presented at the Seminars in Liver Diseases at Camden Yards by Invitation of the Liver Center at the University of Maryland Medical Center. Baltimore, MD, April 13, 1996. 5. Review of Current RTOG Head and Neck Protocols. Presented at Ground Rounds in the Hematology/Medical Oncology Conference, University of Maryland Cancer Center. Baltimore, MD, May 6, 1996. 6. Conformal Radiation Therapy. Presented at the University of Maryland Cancer Center Spring Conference on Advances in Cancer Care. Berkeley Springs, WV, June 14-15, 1996. 7. The Role of Brachytherapy in the Prevention of Coronary Artery Restenosis. Presented at Medical Ground Rounds for the School of Medicine, University of Maryland, Department of Medicine. Baltimore, MD, November 5, 1997. 8. Multidisciplinary Treatment of Non-Small Cell Lung Cancer. Presented at the University of Maryland CME Program. Baltimore, MD, October 21, 1999. 9. Chemo-Radiation Prior to Surgical Resection for Patients Presenting with Advanced Non-Small Cell Cancers of the Lung. Presented at the Symposium for Thoracic Diseases Multi-Disciplinary Conference. Baltimore, MD, December 7, 1999. 10. Innovations in Radiation Oncology. Presented at the Greenebaum Cancer Center Program in Oncology, Cancer Update 2000. Baltimore, MD, November 17, 2000. 11. Combined Modality Therapy for Patients Presenting with Locally Advanced, Non-Small Cell Lung Cancer. Presented at the Thoracic Diseases in the New Millennium Multidisciplinary Conference. Baltimore, MD, December 7, 2001. 12. The Role of Radiation Therapy in the Management of Patients Presenting with Non-Small Cell Lung Cancer. Presented at The Johns Hopkins Lung Cancer Symposium. Baltimore, MD, November 14, 2003. 13. The Role of Tri-Modality Therapy in the Management of Esophageal Carcinoma. Presented at the Symposium for Thoracic Diseases Multidisciplinary Conference. Baltimore, MD, December 12, 2003. 14. Future Directions in the Management of Head and Neck Cancer Patients. Presented at Oncology Ground Rounds, The Reading Hospital. Reading, VA, September 8, 2004. 15. Results of High Dose Chemotherapy for Esophageal Cancer. Presented at the Symposium for Thoracic Diseases Multidisciplinary Conference. Baltimore, MD, December 3, 2004.

23


16. Radiotherapy Techniques for Esophageal Cancer. Presented at the Symposium for Thoracic Diseases Multidisciplinary Conference, Baltimore, MD, October 24, 2008. 17. Changing the Treatment Paradigm for Head & Neck Cancer: The Implications of Biomarkers and HPV. Grand Rounds, Robert W. Johnson Medical Center. New Brunswick, NJ, December 2011. NATIONAL ORAL PRESENTATIONS 1.

Important Predictors of Response Determined by Surgical Stating Prior to Triple Modality Therapy for Esophageal Cancer. Presented to the 39 th Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), Orlando, FL, October 19-22, 1997.

2.

The Use of Concurrent Chemotherapy and Radiation Prior to Surgical Resection in Patients Presenting with Apical Sulcus Tumors. Presented at the 82nd Annual Meeting of the American Radium Society, London, England, April 1-5, 2000.

3.

Clinical Outcomes and Dose Analysis of the Effect of Beta Radiation for the Management of In-Stent Restenosis: Results of the Stents and Radiation Therapy Randomized Trial (START), Presented At the 42nd Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), Boston, MA, October 21-25, 2000.

4.

Combination of Adenovirus p16 (INK4A) Gene Therapy and Ionizing Radiation for Squamous Cell Carcinomas of the Head and Neck. Presented at the Head and Neck Poster Discussion session at the 42nd Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology, October 21-25, 2000.

5.

Patient and Personnel Radiation Exposure During Intravascular Brachytherapy: A Single Institutional Experience with Strontium-90 Isotope, presented at the American Heart Association Meeting, New Orleans, LA, November 15, 2000.

6.

The Importance of Accurate Lymph Node Assessment Prior to Tri-Modality Therapy in Patients Presenting with Esophageal Cancer, presented at the 83 rd Annual American Radium Society, San Diego, CA. April 25-29, 2001.

7.

Analysis of Clinical Outcomes from the START and START 40 Trials: The Efficacy of Sr-90 Radiation in the Treatment of Long Lesion In Stent Restenosis. Presented at the 43 rd Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology, San Francisco, CA, November 7, 2002.

8.

The National Standards of Practice for Patients Receiving Radiation Therapy for Carcinoma of the Esophagus: Results of the 1996-1999 Patterns of Care Study. Accepted for Oral Presentation at the 44th Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology, New Orleans, LA, October 9, 2002.

9.

Outcome Results of the 1996-1999 Patterns of Care Survey of the National Practice for Patients Receiving Radiation Therapy for Carcinoma of the Esophagus. Presented at the 44 th Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology, Salt Lake City, UT, October 22, 2003.

10. Staging of Esophageal Cancer in Patients Treated with Initial Chemoradiation: Findings of the Patterns of Care Study (PCS). Presented at the 45 th Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology, Atlanta, GA, October 5, 2004. 11. Long-Term Clinical Follow-Up of the Phase III Randomized Trial (START) Evaluating the Role of Beta Radiation for the Treatment of In-Stent Restensosis. Presented at the 45 th Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology, Denver, CO,

24


October 17, 2005. 12. A Phase II Trail Evaluating the Efficacy of Weekly Cetuximab, Paclitaxol, Carboplatin and Daily RT in Esophageal Cancer. Presented at the 46th Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology, Philadelphia, PA, November 6, 2006. NATIONAL ORAL PRESENTATIONS – Continued 13. GCC 0442: A Phase II Trial Evaluating the Efficacy of Weekly Cetuximab, Paclitaxel, Carboplatin and Daily RT in Locally Advanced SCCHN. Presented at the ASTRO’s Multidisciplinary Head and Neck Symposium, Palm Springs, CA, January 18 - 20, 2007.

25


Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.